Investment Rating - The report maintains a positive outlook on JD Health, indicating strong sales growth and a favorable investment environment [5][7]. Core Insights - JD Health is expected to maintain robust growth momentum in the second half of 2025, with revenue projected to increase year-on-year, driven by strong performance during the "Double 11" shopping festival and a surge in flu cases in December [5]. - The sales of pharmaceuticals and health products are particularly strong, with adjusted EBITDA expected to double due to margin expansion and operational leverage, offsetting investments in offline stores [5]. - The report highlights that JD Health's direct sales are anticipated to grow year-on-year in the second half of 2025, primarily driven by increased sales of pharmaceuticals and health products during the "Double 11" period [5][6]. Summary by Sections Company Overview - JD Health operates an online retail pharmacy business through self-operated and platform models, focusing on three core categories: pharmaceuticals (including prescription and OTC), health products, and medical devices [10]. Revenue Breakdown - Pharmaceuticals and health products account for 85.3% of revenue, while platform services, advertising, and other sources contribute 14.7% [11]. Market Position - As of February 4, 2026, JD Health's stock price is HKD 60.95, with a market capitalization of USD 26.24 billion and a consensus target price of HKD 76.85 [13].